Xencor Gestione
Criteri Gestione verificati 3/4
Xencor Il CEO è Bassil Dahiyat, nominato in Aug1997, e ha un mandato di 28.92 anni. la retribuzione annua totale è $ 5.52M, composta da 13.5% di stipendio e 86.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.48% delle azioni della società, per un valore di $ 5.37M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 8.9 anni.
Informazioni chiave
Bassil Dahiyat
Amministratore delegato
US$5.5m
Compenso totale
| Percentuale dello stipendio del CEO | 13.45% |
| Mandato del CEO | 28.9yrs |
| Proprietà del CEO | 0.5% |
| Durata media del management | 4yrs |
| Durata media del Consiglio di amministrazione | 8.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 12
XNCR: Future Regulatory Stability And TL1A Pipeline Progress Will Drive Upside
Analysts have adjusted their price target on Xencor by $1, reflecting updated views on the stock after recent research that both lifted the target and questioned the near term catalyst path. Analyst Commentary Bullish Takeaways Bullish analysts highlight the recent US$1 price target adjustment as a signal that updated research still supports upside potential for the stock relative to their prior view.Aggiornamento della narrazione • May 29
XNCR: Future Regulatory Shifts Will Support Oncology Execution Upside
Analysts now estimate Xencor's fair value at about $28.50 per share, a modest change from roughly $28.83 as they factor in updated expectations for revenue growth, profit margins and future P/E following recent price target and rating moves on the stock. Analyst Commentary Recent Street research on Xencor reflects a mix of cautious and constructive views, with JPMorgan adjusting its stance and price target as expectations for catalysts and execution evolve.Articolo di analisi • May 11
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...
Aggiornamento della narrazione • May 02
XNCR: Refined Q4 Assumptions And Regulatory Shifts Will Drive Future Repricing
Analysts have kept Xencor's fair value estimate steady at $43.00, while modestly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E after recent research. This research includes a $1 price target increase to $27 from $26.00, alongside a downgrade based on expectations for fewer near term catalysts.
Aggiornamento della narrazione • Apr 18
XNCR: Mixed Catalyst Outlook And Regulatory Shifts Will Shape Future Repricing
Analysts have increased their price target on Xencor by $1 to $27, citing updated models after the Q4 report, even as some see limited near term catalysts to significantly change the story. Analyst Commentary Recent research on Xencor reflects a more cautious tone, with some high profile firms highlighting limited catalysts and execution risk, even as models are refreshed following the Q4 report.Aggiornamento della narrazione • Apr 03
XNCR: T Cell Engagers And Mixed Catalyst Outlook Will Shape Multi Year Repricing
Narrative Update The analyst fair value estimate for Xencor has been reset from $18.00 to $13.00 as analysts factor in a lack of near term, needle moving catalysts highlighted in recent research, along with updated models following the Q4 report and sector wide reassessments of U.S. biopharmaceutical valuations. Analyst Commentary Recent Street research on Xencor reflects a mix of views, and the reset in fair value has been driven mainly by more cautious commentary around the near term outlook and the timing of impactful catalysts.Aggiornamento della narrazione • Mar 20
XNCR: Sector Tailwinds And T Cell Engagers Will Drive Multi Year Repricing
Analysts have nudged their Xencor models after recent sector-wide updates and the latest Q4 report, with Street price targets moving into a roughly $20 to $27 range. The internal fair value anchor in this framework holds near $18, reflecting tempered revenue and margin assumptions offset by supportive biopharma sentiment.Aggiornamento della narrazione • Mar 06
XNCR: Reset Pipeline Milestones And Sector Tailwinds Will Drive Repricing
Analysts have raised their Xencor fair value estimate from $40.00 to $43.00, reflecting refreshed models and higher Street price targets, including recent moves to $27 and $20, supported by updated company assumptions and broader biotech sector drivers cited in recent research. Analyst Commentary Recent Street research on Xencor points to a more constructive stance on the stock, with bullish analysts revisiting their models after the latest quarterly update and broader sector checks.Aggiornamento della narrazione • Feb 20
XNCR: T Cell Engagers In Solid Tumors Will Drive Multi Year Repricing
Analysts raised their Xencor price target to $20 from $17, citing an improving environment for U.S. biotech funding and deal activity, as well as greater market recognition of recent positive data catalysts. Analyst Commentary Recent commentary around Xencor frames the higher US$20 price target within a broader reassessment of U.S. biopharmaceutical names.Articolo di analisi • Feb 13
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate
Key Insights Xencor's estimated fair value is US$16.09 based on 2 Stage Free Cash Flow to Equity Xencor's US$11.62...Aggiornamento della narrazione • Feb 06
XNCR: Constructive Biopharma Backdrop Will Support Future Oncology Upside
Narrative Update Analysts have nudged their 12 month price target for Xencor higher from US$17 to US$20, citing a more constructive backdrop for U.S. biopharmaceuticals, improving access to capital, supportive M&A activity, and recent positive data catalysts now being reflected in valuations. Analyst Commentary Recent commentary around Xencor centers on how it fits into a broader recovery in U.S. biopharmaceuticals, with the new US$20 price target reflecting both improved sector conditions and ongoing uncertainty about how durable these supports will be.Aggiornamento della narrazione • Jan 23
XNCR: T Cell Engagers And TL1A Pipeline Will Drive Multi Year Repricing
Analysts have nudged their price targets on Xencor higher to a range of US$20 to US$42, pointing to positive recent data readouts, a more constructive view on the T cell engager and TL1A pipeline, and a generally more supportive biotech funding backdrop. Analyst Commentary Recent Street research on Xencor clusters around a more constructive view of its T cell engager and TL1A programs, but opinions are not uniformly bullish.Aggiornamento della narrazione • Jan 08
XNCR: T Cell Engager Pipeline Progress Will Drive Multi Year Repricing Potential
Narrative Update Analysts have lifted their Xencor fair value estimate from US$8.67 to US$18.00. This change reflects higher Street price targets in the US$20 to US$42 range and growing confidence in the company's T cell engager pipeline following recent data updates and conference presentations.Seeking Alpha • Jan 01
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
Summary XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties. This approach lets them partially fund their internal R&D. But on top of that, XNCR has ample liquid resources it can tap into as needed. XNCR’s lead immunology asset XmAb942 is in Phase 2b for ulcerative colitis. And this candidate could help validate their ability to advance late-stage assets internally. Management also believes that RCC spending is concentrated in a few branded therapies. This could prove an interesting opportunity for their platform. Thus, I feel XNCR offers compelling upside potential with its drug candidates for long-term investors, despite its inherent early-stage and partner risks. Read the full article on Seeking AlphaAggiornamento della narrazione • Dec 18
XNCR: Advancing T Cell Engagers Will Drive Future Oncology Upside
We are nudging our Xencor fair value estimate slightly higher to $28.25 from $28.00, reflecting analysts' increased price targets and improved sentiment around the company's T cell engager and TL1A antibody programs following encouraging early stage data and clearer late stage development visibility. Analyst Commentary Recent Street research reflects a constructive but still risk balanced view on Xencor, with multiple firms lifting price targets as they factor in stronger T cell engager data and growing conviction in the TL1A program, while still highlighting execution and clinical readout risks that could impact long term value realization.Aggiornamento della narrazione • Dec 04
XNCR: Advancing T Cell Engager Pipeline Will Drive Future Upside Potential
Xencor's analyst price target has inched higher to about $28.00 from roughly $27.91, as analysts factor in stronger long term value from the company's advancing T cell engager and TL1A antibody programs, despite modest tweaks to growth and margin assumptions. Analyst Commentary Recent Street research reflects a generally improving stance on Xencor, with several bullish analysts lifting price targets as confidence grows in the company’s T cell engager and TL1A programs, while more cautious voices continue to emphasize execution and clinical risk.Articolo di analisi • Nov 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise
Xencor, Inc. ( NASDAQ:XNCR ) shares have continued their recent momentum with a 27% gain in the last month alone...Aggiornamento della narrazione • Nov 20
XNCR: Advancing Late-Stage Antibody Programs Will Drive Upside Into 2025
The analyst price target for Xencor edged higher to $27.91 from $27.64 after analysts cited improved revenue growth outlook and progress across key clinical programs. Analyst Commentary Recent Street research on Xencor reflects a range of views, with several analysts updating their models and outlooks following new data from clinical programs and company updates.Aggiornamento della narrazione • Nov 05
XNCR: Positive Early Oncology Data Will Accelerate Future Upside Potential
Xencor's analyst price target has increased from $25.73 to $27.64, with analysts citing positive pipeline updates and an improved outlook on novel oncology programs as drivers of the higher valuation. Analyst Commentary Analyst sentiment on Xencor has shifted notably in recent months, reflecting emerging data from clinical studies and evolving perspectives on the company's future growth potential.Aggiornamento della narrazione • Oct 22
Analysts Weigh Xencor Pipeline Progress as Price Targets Inch Higher on Positive Data
The analyst price target for Xencor has increased modestly, rising by $0.18 per share as analysts cite encouraging initial data for its XmAb819 therapy and a slightly improved outlook on pipeline progress, despite ongoing development challenges. Analyst Commentary Recent Street research provides a mixed outlook on Xencor, reflecting both optimism around its emerging therapies and caution due to the company's ongoing development challenges and market execution risks.Aggiornamento della narrazione • Oct 08
IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have raised their price target for Xencor from $24.10 to $25.55 per share. This reflects moderate optimism despite concerns around limited near-term catalysts and extended development timelines described in recent research commentary.Articolo di analisi • Sep 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise
Xencor, Inc. ( NASDAQ:XNCR ) shareholders have had their patience rewarded with a 31% share price jump in the last...Articolo di analisi • Sep 18
Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento della narrazione • Aug 22
IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have reduced their price target for Xencor to $25.20 amid optimism for key pipeline assets but tempered by concerns over limited data, lack of near-term catalysts, and execution speed. Analyst Commentary Stock price seen as undervaluing Xencor's three main business pillars: IBD franchise led by '942, immunology efforts led by plamotamab, and the oncology bispecific platform.Articolo di analisi • Aug 06
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking
NasdaqGM:XNCR 1 Year Share Price vs Fair Value Explore Xencor's Fair Values from the Community and select yours With a...Nuova narrazione • Jul 06
IBD Biologics And TL1A Programs Will Forge New Paths
Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability.Articolo di analisi • Apr 26
Is Xencor (NASDAQ:XNCR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Mar 30
Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
To the annoyance of some shareholders, Xencor, Inc. ( NASDAQ:XNCR ) shares are down a considerable 27% in the last...Articolo di analisi • Feb 04
Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%
Xencor, Inc. ( NASDAQ:XNCR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Seeking Alpha • Jan 30
Xencor: Substantial Promise, Slow Progress
Summary Today, I revisit Xencor, Inc., a developmental biotech concern for the first time since 2017. The company is advancing a diverse pipeline that consists of both licensed and wholly owned candidates. Xencor has a strong cash position, projecting $707 million in cash and marketable securities by year-end, bolstered by a recent $200 million secondary offering. Xencor's pipeline has some significant promise, but progress has been notably slow over the years. An updated analysis around Xencor follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • Dec 31
Is Xencor (NASDAQ:XNCR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Dec 03
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Despite an already strong run, Xencor, Inc. ( NASDAQ:XNCR ) shares have been powering on, with a gain of 26% in the...Articolo di analisi • Nov 10
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders of Xencor, Inc. ( NASDAQ:XNCR ) will be pleased this week, given that the stock price is up 11% to...Seeking Alpha • Sep 12
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Summary Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD. The global market for inflammatory bowel disease is expected to cross $30 billion by 2031. Read the full article on Seeking AlphaArticolo di analisi • Sep 12
Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up
Xencor, Inc. ( NASDAQ:XNCR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...Articolo di analisi • Sep 06
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Key Insights The projected fair value for Xencor is US$16.92 based on 2 Stage Free Cash Flow to Equity With US$16.32...Articolo di analisi • Jul 13
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 16
Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Xencor, Inc. ( NASDAQ:XNCR ) is a stock worth...Articolo di analisi • Mar 27
Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Feb 27
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Despite an already strong run, Xencor, Inc. ( NASDAQ:XNCR ) shares have been powering on, with a gain of 29% in the...Seeking Alpha • Feb 03
Xencor: Standing Out With XmAb Technology
Summary Xencor demonstrates strong YoY revenue growth through achieved milestones with major industry partners. The strategic sale of royalty interests strengthens Xencor's balance sheet and provides flexibility for future strategic moves. Xencor's pipeline developments and clinical trials show a focus on promising therapies in oncology and autoimmune diseases. Read the full article on Seeking AlphaArticolo di analisi • Jan 05
Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 9.3x Xencor, Inc. ( NASDAQ:XNCR ) is a stock worth...Articolo di analisi • Nov 13
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...Articolo di analisi • Nov 10
Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Aug 08
Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Shareholders in Xencor, Inc. ( NASDAQ:XNCR ) may be thrilled to learn that the analysts have just delivered a major...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$172m |
| Dec 31 2025 | US$6m | US$743k | -US$92m |
| Sep 30 2025 | n/a | n/a | -US$131m |
| Jun 30 2025 | n/a | n/a | -US$171m |
| Mar 31 2025 | n/a | n/a | -US$208m |
| Dec 31 2024 | US$7m | US$721k | -US$233m |
| Sep 30 2024 | n/a | n/a | -US$213m |
| Jun 30 2024 | n/a | n/a | -US$191m |
| Mar 31 2024 | n/a | n/a | -US$146m |
| Dec 31 2023 | US$8m | US$700k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$119m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$140m |
| Dec 31 2022 | US$8m | US$670k | -US$55m |
| Sep 30 2022 | n/a | n/a | US$30m |
| Jun 30 2022 | n/a | n/a | US$22m |
| Mar 31 2022 | n/a | n/a | US$109m |
| Dec 31 2021 | US$5m | US$625k | US$83m |
| Sep 30 2021 | n/a | n/a | -US$4m |
| Jun 30 2021 | n/a | n/a | US$24m |
| Mar 31 2021 | n/a | n/a | -US$64m |
| Dec 31 2020 | US$4m | US$600k | -US$69m |
| Sep 30 2020 | n/a | n/a | -US$83m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$4m | US$567k | US$27m |
Compensazione vs Mercato: La retribuzione totale di Bassil ($USD 5.52M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.54M ).
Compensazione vs guadagni: La retribuzione di Bassil è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Bassil Dahiyat (56 yo)
28.9yrs
Mandato
US$5,521,205
Compensazione
Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 28.9yrs | US$5.52m | 0.48% $ 5.4m | |
| Senior VP & CFO | 2.3yrs | US$1.64m | 0.037% $ 415.8k | |
| Executive VP of Research & Chief Scientific Officer | 12yrs | US$1.98m | 0.29% $ 3.2m | |
| Senior VP | 6.8yrs | US$1.57m | 0.053% $ 588.6k | |
| Associate Director and Head of Corporate Communications & Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VIce President of Human Resources | 4.9yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 4.5yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Program Leadership & Alliance Management | 3.5yrs | Nessun dato | Nessun dato | |
| Executive VP & Chief Strategy Officer | 2.5yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development (Autoimmune) | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Clinical Development- Oncology | less than a year | Nessun dato | Nessun dato |
4.0yrs
Durata media
56yo
Età media
Gestione esperta: Il team dirigenziale di XNCR è considerato esperto (durata media dell'incarico 4 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 28.9yrs | US$5.52m | 0.48% $ 5.4m | |
| Independent Director | 1.3yrs | US$624.80k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$344.24k | 0.018% $ 205.6k | |
| lead Independent Director | 11.3yrs | US$376.74k | 0.021% $ 233.2k | |
| Independent Director | 9.3yrs | US$336.74k | 0.015% $ 170.7k | |
| Director | 1yr | US$537.94k | Nessun dato | |
| Member of Scientific Advisory Board | 17.1yrs | Nessun dato | Nessun dato | |
| Independent Director | 7.7yrs | US$342.24k | 0.017% $ 185.1k | |
| Independent Director | 12yrs | US$340.74k | 0.020% $ 220.6k | |
| Independent Director | 2.8yrs | US$337.99k | 0.0081% $ 89.7k |
8.9yrs
Durata media
69yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di XNCR sono considerati esperti (durata media dell'incarico 8.9 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/06 11:17 |
| Prezzo dell'azione a fine giornata | 2026/07/02 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Xencor, Inc. è coperta da 24 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Zhiqiang Shu | Berenberg |